Gastroenteropancreatic SCNEC displayed comparable DLL3 expression levels compared to their pulmonary counterparts, indicating a relatively consistent expression pattern for this morphologic variant of NEC, giving hope that DLL3-targeted therapies might have a similar efficacy in extrapulmonary SCNEC. The gene discussed is DLL3; the disease is neuroendocrine carcinoma.